199 related articles for article (PubMed ID: 21055812)
21. Altered vascular microenvironment by bevacizumab in diabetic fibrovascular membrane.
Nakao S; Ishikawa K; Yoshida S; Kohno R; Miyazaki M; Enaida H; Kono T; Ishibashi T
Retina; 2013 May; 33(5):957-63. PubMed ID: 23503340
[TBL] [Abstract][Full Text] [Related]
22. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy.
Ishikawa K; Honda S; Tsukahara Y; Negi A
Eye (Lond); 2009 Jan; 23(1):108-11. PubMed ID: 17891057
[TBL] [Abstract][Full Text] [Related]
23. Decreased prothrombin time after intravitreal bevacizumab in the early period in patients with proliferative diabetic retinopathy.
Qian J; Jiang YR
Acta Ophthalmol; 2011 Jun; 89(4):e332-5. PubMed ID: 21470390
[TBL] [Abstract][Full Text] [Related]
24. Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection.
Xu Y; Zhang Q; Kang X; Zhu Y; Li J; Chen Y; Zhao P
Acta Ophthalmol; 2013 Jun; 91(4):e304-10. PubMed ID: 23647944
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
26. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
Naser H; Koss MJ; Singh P; Koch F
Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
[TBL] [Abstract][Full Text] [Related]
27. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
[TBL] [Abstract][Full Text] [Related]
28. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
[TBL] [Abstract][Full Text] [Related]
30. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection.
Kohno R; Hata Y; Mochizuki Y; Arita R; Kawahara S; Kita T; Miyazaki M; Hisatomi T; Ikeda Y; Aiello LP; Ishibashi T
Am J Ophthalmol; 2010 Aug; 150(2):223-229.e1. PubMed ID: 20542485
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery.
Takamura Y; Kubo E; Akagi Y
Ophthalmology; 2009 Jun; 116(6):1151-7. PubMed ID: 19376589
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
[TBL] [Abstract][Full Text] [Related]
33. [Use of bevacizumab in the treatment of complicated proliferative diabetic retinopathy].
Benhmidoune L; McHachi A; Boukhrissa M; Chakib A; Rachid R; Elbelhadji M; Amraoui A
J Fr Ophtalmol; 2013 Nov; 36(9):758-63. PubMed ID: 23830522
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.
Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M
Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
36. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy.
Hattori T; Shimada H; Nakashizuka H; Mizutani Y; Mori R; Yuzawa M
Retina; 2010 May; 30(5):761-4. PubMed ID: 20453802
[TBL] [Abstract][Full Text] [Related]
37. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.
Saito M; Shiragami C; Shiraga F; Kano M; Iida T
Am J Ophthalmol; 2010 Mar; 149(3):472-81.e1. PubMed ID: 20053392
[TBL] [Abstract][Full Text] [Related]
38. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; RodrÃguez FJ; Udaondo-Mirete P;
Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes.
Yanyali A; Aytug B; Horozoglu F; Nohutcu AF
Am J Ophthalmol; 2007 Jul; 144(1):124-6. PubMed ID: 17601433
[TBL] [Abstract][Full Text] [Related]
40. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]